| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Theodore Daniel Zucconi last filed a Form 4 in April 2018, as Director at GALT. Theodore Daniel Zucconi's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 1,083 shares of GALT. The GALT filings lean toward selling, a net 3,000 shares.
Theodore Daniel Zucconi has 5 Form 4 filings on record from December 2016 to April 2018, all as Director at Galectin Therapeutics (GALT), 2016–2018.
The 7 reported transactions were 3 open-market sales, 2 option or other derivative awards, 1 option exercise and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $2K and 1 sale worth about $14K.
The only open-market purchase was 1,000 shares of GALT at an average $2.27 on May 23, 2017, about $2K.
The only open-market sale was 4,000 shares of GALT at an average $3.58 on April 16, 2018, about $14K.
Shares as reported in the last Form 4 for each company; the most recent is from April 2018. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.